237 related articles for article (PubMed ID: 35809234)
1. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
Chang D; Truong E; Mena EA; Pacheco F; Wong M; Guindi M; Todo TT; Noureddin N; Ayoub W; Yang JD; Kim IK; Kohli A; Alkhouri N; Harrison S; Noureddin M
Hepatology; 2023 Feb; 77(2):546-557. PubMed ID: 35809234
[TBL] [Abstract][Full Text] [Related]
2. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
3. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
[TBL] [Abstract][Full Text] [Related]
4. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
Bertot LC; Jeffrey GP; de Boer B; Wang Z; Huang Y; Garas G; MacQuillan G; Wallace M; Smith BW; Adams LA
Dig Dis Sci; 2023 Jun; 68(6):2757-2767. PubMed ID: 36947289
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Pennisi G; Enea M; Falco V; Aithal GP; Palaniyappan N; Yilmaz Y; Boursier J; Cassinotto C; de Lédinghen V; Chan WK; Mahadeva S; Eddowes P; Newsome P; Karlas T; Wiegand J; Wong VW; Schattenberg JM; Labenz C; Kim W; Lee MS; Lupsor-Platon M; Cobbold JFL; Fan JG; Shen F; Staufer K; Trauner M; Stauber R; Nakajima A; Yoneda M; Bugianesi E; Younes R; Gaia S; Zheng MH; Cammà C; Anstee QM; Mózes FE; Pavlides M; Petta S
Hepatology; 2023 Jul; 78(1):195-211. PubMed ID: 36924031
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Han S; Choi M; Lee B; Lee HW; Kang SH; Cho Y; Ahn SB; Song DS; Jun DW; Lee J; Yoo JJ
Gut Liver; 2022 Nov; 16(6):952-963. PubMed ID: 35193993
[TBL] [Abstract][Full Text] [Related]
7. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
[TBL] [Abstract][Full Text] [Related]
8. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
10. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
11. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
12. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
13. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
[TBL] [Abstract][Full Text] [Related]
15. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
[TBL] [Abstract][Full Text] [Related]
16. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
17. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease.
Li Q; Huang C; Xu W; Hu Q; Chen L
Medicine (Baltimore); 2020 Jun; 99(23):e20616. PubMed ID: 32502037
[TBL] [Abstract][Full Text] [Related]
19. Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients.
Ito T; Nguyen VH; Tanaka T; Park H; Yeh ML; Kawanaka M; Arai T; Atsukawa M; Yoon EL; Tsai PC; Toyoda H; Huang JF; Henry L; Jun DW; Yu ML; Ishigami M; Nguyen MH; Cheung RC
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1013-1022.e6. PubMed ID: 35654298
[TBL] [Abstract][Full Text] [Related]
20. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]